es > en

> Hemopurification therapies

CYTOSORB®, a world leader in intensive care immunotherapy and cardiac surgery, offers a revolutionary medical response to critically ill patients with SEPSIS or secondary hyperinflation to multiple etiologies induced by inflammatory mediators

SEPSIS is one of the hospital problems with the highest prevalence and mortality. More than 50% of ICU patients is affected by SEPSIS and the multiorgan failure is the cause of almost half of the deaths. There are not effective therapies available today.

 

CYTOSORB®, a world leader in intensive care immunotherapy and cardiac surgery, offers a revolutionary medical response to critically ill patients with SEPSIS or secondary hyperinflation to multiple etiologies induced by inflammatory mediators, pathogens, Pathogen-associated Molecular Pattern molecules (PAMPs), traumas, hemorrhages, chemicals, DAMPs and radiation.

This maladaptive and potentially fatal inflammation can cause physiopathological changes such as: massive induction of nitric oxide, myocardial depression, peripheral vasodilation and shock, Systemic Capillary Leak Syndrome, loss of intravascular volume, tissue edema, pulmonary edema, respiratory and circulatory failure, abnormal marginalization of activated leukocytes to other healthy organs, apoptosis, susceptibility to new infections, glycocalyx damage and endothelial injury, microthrombi and microcirculatory dysfunction, Disseminated Intravascular Coagulation, hemorrhage, loss of gastrointestinal mucosal integrity, etc.
 

Is well known the harmful role of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6 and others in SIRS, but it’s not known at all the deleterious role of excessive anti-inflammatory cytokines (eg IL-4, IL-10, IL-1a) under these conditions. Often mistakenly named as "good cytokines," these anti-inflammatory cytokines mediate the Compensatory Anti-inflammatory Response syndrome (CARS)  and can lead to profound immune suppression, called "immune paralysis," leading to a predisposition to nosocomial infections and bad healing.

CYTOSORB’s® therapy consists of the purification through hemoabsorption with nanotechnology through an exclusive polymer beads that physiologically modulate the immune response, without eliminating it completely and focusing the defensive response in the pathological focus and not in a systemic way.
It discriminates from a defined molecular cut-off size that makes it especially efficient with the cytokine storm (interleukins) and other hydrophobic substances or toxins (Ammonium, Bilirubin, Biliary Acids, Mioglobin, as well as DAMPS and PAMPS associated with bacterial endotoxins), but without affecting beneficial substances like albumin.
Technically, it is very easy to install and adaptable to any extracorporeal perfusion system (except peritoneal HD): Hemodialysis, Hemofiltration, Bypass, ECMO, HemoPerfusion.


Particularly indicated in cases of:

  • Sepsis or SIRS (Systemic Inflammatory Response Syndrome)
  • Heart surgery
  • Politrauma and rhabdomyolysis
  • Serious burn injury
  • Severe pancreatitis
  • Elimination of liver toxins
  • Cardiogenic shock
  • Surgery complications
  • Use with ECMO
  • Meningitis, Dengue, some toxics, etc

 

 

> Share in